180302-28-7

Upstream product

• 180302-27-6 2-Fluoro-5-((3aS,4R,8R,8aS)-4,7,8-tribenzyl-2,2-dimethyl-6-oxo-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl)-benzonitrile 
• 170870-15-2 (1R,1'R)-1,1'-((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(2-phenylethanamine) 
• 170028-72-5 (3aS,4R,8R,8aS)-4,8-dibenzyl-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-e][1,3]diazepin-6(7H)-one 
• 170028-71-4 N'-((R)-1-{(4S,5S)-5-[(R)-1-(N',N'-Dimethyl-hydrazino)-2-phenyl-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-phenyl-ethyl)-N,N-dimethyl-hydrazine 
• 212831-59-9 (3aS,4R,8R,8aS)-4,5,8-Tribenzyl-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 

Relevant academic research and scientific papers

Synthesis, antiviral activity and pharmacokinetics of P1/P1′ substituted 3-aminoindazole cyclic urea HIV protease inhibitors

A series of P1/P1′ substituted cyclic urea analogues were prepared in an attempt to increase the intra-cellular antiviral potency of the nonsymmetrical 3-aminoindazoles DMP 850 and DMP 851. The effect of alkyl substitution of the P1/P1′ residues on cellul